CN207950205U - A kind of Nano medication slow-released carrier as ophthalmic administration - Google Patents
A kind of Nano medication slow-released carrier as ophthalmic administration Download PDFInfo
- Publication number
- CN207950205U CN207950205U CN201721512718.4U CN201721512718U CN207950205U CN 207950205 U CN207950205 U CN 207950205U CN 201721512718 U CN201721512718 U CN 201721512718U CN 207950205 U CN207950205 U CN 207950205U
- Authority
- CN
- China
- Prior art keywords
- drug
- nanogel
- ophthalmic administration
- nano medication
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 229940079593 drug Drugs 0.000 title claims abstract description 33
- 238000000926 separation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000969 carrier Substances 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model is related to a kind of Nano medication slow-released carriers as ophthalmic administration, include the nanogel ontology of hemisphere structure, and the nanogel ontology includes the optics area at center and the outer zone around central part, and drug is coated in the outer zone.The contact area of the nanogel ontology of semiglobe, drug and eyes is big, and using nanogel slow releasing pharmaceutical, the effect lasts of drug are efficient.
Description
Technical field
The utility model is related to field for the treatment of of eye disorders more particularly to a kind of Nano medication sustained releases as ophthalmic administration
Carrier.
Background technology
For the prevention or therapeutic effect for reaching best, many diseases or state are needed to give drug or bioactive substance
And reach stable or lasting levels of drugs in vivo.To achieve the above object, prior art means using multiple dose administration or
Person is realized using the system of sustainable drug release or controllable drug release.Wherein, it refers to by certain that more meterings, which are also known as repeat administration,
The medication that administration makes blood concentration reach and is maintained in therapeutic window is repeated several times in dosage, certain intervals time.Clinically
Often through multiple dose administration to maintain blood concentration in therapeutic window.Principle is to calculate injection or medication according to blood concentration
Amount, the single drug duration is short, needs repeatedly to be administered patient.And controlled release pharmaceutical compositions have two big main advantages,
First, higher treatment level can be maintained in longer time, second is that can subtract while reaching with quick releasing formulation same effect
Few medicining times, to improve the compliance of patient.Slow release method is efficiently used, drug is implanted directly into lesions position, when long
Between be sustained drug effect, can not only mitigate the pain of patient, also can the release of more scientific and reasonable control drug effect.Wherein, hydrogel conduct
Pharmaceutical carrier plays an important role in terms of medicine controlled releasing.The response performance of hydrogel be by the reversible volumetric phase transformation of gel come
It realizes, and makes it in the fixation etc. of sensor, artificial muscle, drug controlled release, organizational project, catalyst system and catalyzing, enzyme
It has broad application prospects.
Currently, European and American developed countries have started the clinical application of similar technique many years ago.Such as chip implanted prosthetics, drug
It is big to be sustained side effect, silica gel stick technology is there are nondegradable defect, and patient must face the pain of second operation, and small plant
Enter in body technique, since release amount of medicine is uncontrollable, there is also huge side effects.And it is newest research shows that nanometer
Gel, which can be loaded, to be sent to inside cell and passes through biomembrane.This nanogel has good stability and can protect
Shield bioactie agent is not degraded by endocellular metabolism system.Nanogel conveys and improves oral and brain in systemic medication
Prodigious potential is shown in terms of the bioavilability of position.
Currently, when ophthalmology disease uses medicament, the drug of eyedrops class is inconvenient for use, is easy to drip to outside eye socket；And it clicks and enters
Liquid medicine after intraocular, is diluted by tear quickly, reduces drug effect, on the other hand makes that drug effect is of short duration, curative effect is unstable, treatment
It is ineffective.
Utility model content
In view of the above-mentioned state of the art, persistently delay the technical problem to be solved by the utility model is to provide a kind of
It releases, and increases contact area.
Technical solution is used by the utility model solves above-mentioned technical problem：A kind of nanometer medicine as ophthalmic administration
Object slow-released carrier, includes the nanogel ontology of hemisphere structure, and the nanogel ontology includes optics area and the ring at center
Around the outer zone of central part, drug is coated in the outer zone.
Further, the drug is isodistantly spaced radial separation and opens.Drug is evenly distributed, and drug effect is more balanced.
It is the utility model compared with prior art that the utility model, which solves technical solution used by above-mentioned technical problem,
Advantageous effect be：The contact area of the nanogel ontology of semiglobe, drug and eyes is big, utilizes nanogel slow releasing medicinal
The effect lasts of object, drug are efficient.
Description of the drawings
Fig. 1 is novel overall structure diagram described in the utility model；
Fig. 2 is novel integrally-built another schematic diagram described in the utility model.
Specific implementation mode
The following will be combined with the drawings in the embodiments of the present invention, to the skill embodiment in the utility model embodiment, and
The embodiment being not all of.Based on the embodiments of the present invention, those of ordinary skill in the art are not making creativeness
The every other embodiment obtained under the premise of labour, shall fall within the protection scope of the present invention.
As shown in Figs. 1-2, a kind of Nano medication slow-released carrier as ophthalmic administration, including the nanometer of hemisphere structure are solidifying
Glue ontology, the nanogel ontology includes the optics area 2 at center and the outer zone 1 around central part, in the outer zone 1
Inside it is coated with drug.
Further, the drug is isodistantly spaced radial separation and opens.Drug is evenly distributed, and drug effect is more balanced.
Its preparation process can be laser processing or 3D printing.
It is the utility model compared with prior art that the utility model, which solves technical solution used by above-mentioned technical problem,
Advantageous effect be：The contact area of the nanogel ontology of semiglobe, drug and eyes is big, utilizes nanogel slow releasing medicinal
The effect lasts of object, drug are efficient.
It is obvious to a person skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and
And without departing substantially from the spirit or essential attributes of the utility model, it can realize that this practicality is new in other specific forms
Type.Therefore, in all respects, the present embodiments are to be considered as illustrative and not restrictive, this practicality is new
The range of type is indicated by the appended claims rather than the foregoing description, it is intended that containing in the equivalent requirements of the claims will be fallen
All changes in justice and range are embraced therein.Any reference numeral in claim should not be considered as limitation
Involved claim.
Claims (3)
1. a kind of Nano medication slow-released carrier as ophthalmic administration, which is characterized in that include the nanogel of hemisphere structure
Ontology, the nanogel ontology include the optics area at center and the outer zone around central part, are wrapped in the outer zone
It is covered with drug.
2. a kind of Nano medication slow-released carrier as ophthalmic administration according to claim 1, which is characterized in that the medicine
Object is isodistantly spaced radial separation and opens.
3. a kind of Nano medication slow-released carrier as ophthalmic administration according to claim 1, which is characterized in that described half
The nanogel body thickness of sphere structure is 1mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201721512718.4U CN207950205U (en) | 2017-11-06 | 2017-11-06 | A kind of Nano medication slow-released carrier as ophthalmic administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201721512718.4U CN207950205U (en) | 2017-11-06 | 2017-11-06 | A kind of Nano medication slow-released carrier as ophthalmic administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN207950205U true CN207950205U (en) | 2018-10-12 |
Family
ID=63724681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201721512718.4U Expired - Fee Related CN207950205U (en) | 2017-11-06 | 2017-11-06 | A kind of Nano medication slow-released carrier as ophthalmic administration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN207950205U (en) |
-
2017
- 2017-11-06 CN CN201721512718.4U patent/CN207950205U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021147598A1 (en) | Application of and preparation method for cationic polymer modified by fluorine-containing compound as drug carrier | |
| JP6121674B2 (en) | Microneedle rapid dissolution method | |
| ES2978875T3 (en) | Water-soluble microneedle spikes and non-aqueous cosmetic composition containing them | |
| Goyal et al. | Non-invasive systemic drug delivery through mucosal routes | |
| CN104274390B (en) | A kind of long-acting preparation capable of permeating skin of timolol and its application in hemangioma | |
| CN101554369B (en) | External spraying agent and eye drop of compound oil nano-emulsion as well as preparation method thereof | |
| CN102600110B (en) | Glucosamine cataplasm, preparation method thereof and application | |
| Zhang et al. | Microneedle-enabled therapeutics delivery and biosensing in clinical trials | |
| CN109833311A (en) | A kind of molten film composition of mouth | |
| Mustfa et al. | Nanomedicine approaches to negotiate local biobarriers for topical drug delivery | |
| US20170100574A1 (en) | Apparatus configured for accurate up-loading of a single dose onto a delivery applicator | |
| CN103948573A (en) | Preparation method of nasal linalool-borneol preparation capable of calming, assisting sleeping and relieving palpitation | |
| CN112022919A (en) | Percutaneous-absorption artemisia vulgaris oil carrier gel and preparation method thereof | |
| Jiang et al. | Advances in microneedle patches for long-acting contraception | |
| CN113244380B (en) | Temperature-sensitive gel injury repair preparation and application thereof | |
| Li et al. | Applications of capillary action in drug delivery | |
| CN207950205U (en) | A kind of Nano medication slow-released carrier as ophthalmic administration | |
| CN106214624A (en) | For treating timolol maleate preparation and the application thereof of baby's Superficial hemangioma | |
| CN103269693A (en) | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging | |
| DE102022128062A1 (en) | Platform technology for the treatment of inflammatory, immunological and/or autoimmunological diseases | |
| CN105796645A (en) | Concealed nasal patch capable of reliving rhinobyon and preparation method of concealed nasal patch | |
| JP2022507646A (en) | Uses of braiaconitine A | |
| CN208003121U (en) | A kind of storage unit for stablizing sustained release Nano medication | |
| CN207950204U (en) | A kind of storage unit of injection-type Nano medication | |
| CN208611373U (en) | A kind of storage unit of the Nano medication convenient for operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181012 |